The COVID-19 pandemic is disproportionately affecting children with attention-deficit/hyperactivity disorder (ADHD) and other educational challenges, Greg Mattingly, MD, said at a recent conference session.
After losing a night’s sleep, people with high but subclinical attention-deficit/hyperactivity disorder (ADHD) traits performed worse on tasks involving attentional regulation and emotional control than people with low ADHD traits did.
A machine-learning analysis misclassified only 5% of adults with attention-deficit/hyperactivity disorder in a study that also included adults with obesity or problematic gambling and control subjects.
Consistent participation in extracurricular sports during the elementary school years predicted fewer attention-deficit/hyperactivity disorder (ADHD) symptoms at age 12 in girls—but not in boys, according to a study in Preventive Medicine.
Children with attention-deficit/hyperactivity disorder (ADHD) who are African American appear to have key genetic differences from those who are Caucasian, according to a study published in Scientific Reports.
AR19, an investigational stimulant for attention-deficit/hyperactivity disorder (ADHD), improved symptoms in adults with ADHD in a Phase 3 trial, according to a poster presented at Psych Congress 2020.
The US Food and Drug Administration has accepted the filing of a New Drug Application for an investigational amphetamine for the treatment of attention-deficit/hyperactivity disorder specifically designed to resist manipulation.